Screener
Vertex Pharmaceuticals VRTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
FAQ
- What is Vertex Pharmaceuticals's accounts payable?
- Vertex Pharmaceuticals (VRTX) reported accounts payable of $489.3M in Q1 2026.
- How has Vertex Pharmaceuticals's accounts payable changed year-over-year?
- Vertex Pharmaceuticals's accounts payable increased by 10.0% year-over-year, from $445M to $489.3M.
- What is the long-term trend for Vertex Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's accounts payable has grown at a 24.4% compound annual growth rate (CAGR), from $155.1M to $461.7M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Vertex Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude